Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
NCT01349855
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG:
Insulin glargine HOE901
Sponsor
Sanofi